Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men / Christina Wang, Glenn Cunningham, Adrian Dobs, Ali Iranmanesh, Alvin M. Matsumoto, Peter J. Snyder, Thomas Weber, Nancy Berman, Laura Hull, Ronald S. Swerdloff. - (The Journal of Clinical Endocrinology & Metabolism 89 (2004) 5 (1 May); p. 2085-2098)

  • PMID: 15126525
  • DOI: 10.1210/jc.2003-032006


Abstract

Transdermal testosterone (T) delivery represents an effective alternative to injectable androgens. We studied 163 hypogonadal men who applied 5, 7.5, or 10 g AndroGel (T gel) 1% CIII per day for up to 42 months. Efficacy data were presented in 123 subjects considered evaluable. Continuous AndroGel treatment normalized mean serum T and free T levels. Mean serum 5alpha-dihydrotestosterone concentrations and 5alpha-dihydrotestosterone/T ratio slightly increased, mean serum estradiol/T ratio doubled, and mean serum FSH and LH levels were suppressed by T replacement. Sexual function and mood parameters improved rapidly and were maintained throughout T treatment. Lean body mass increased (P = 0.0001) and fat mass decreased (P = 0.0001), and these changes were maintained with treatment but were not accompanied by significant increases in muscle strength. Increases in serum bone markers suggestive of increased bone formation were followed by gradual and progressive increases in bone mineral density more in the spine (P = 0.0001) than the hip (P = 0.0004). Mild local skin irritation occurred in 12 subjects, resulting in discontinuation in only one subject. Except for the anticipated increase in hematocrit and hemoglobin, there were no clinically significant changes in blood counts or biochemistry. In three subjects with elevated serum prostate-specific antigen, prostate biopsies showed cancer. We conclude that continued application of AndroGel resulted in beneficial effects similar to those with injectables and other transdermal preparations. This study was neither placebo controlled nor powered to determine the effects of T treatment on prostate cancer risk. Thus, monitoring for prostatic disease and assessment for erythrocytosis are strongly advised to reduce the risk of adverse events with T treatment of hypogonadal men.

Original document

Parameters

Science
Study
Date
1 May 2004
People
Berman, Nancy
Cunningham, Glenn
Dobs, Adrian
Hull, Laura
Iranmanesh, Ali
Matsumoto, Alvin M.
Snyder, Peter J.
Swerdloff, Ronald S.
Wang, Christina
Weber, Thomas
Country
United States of America
Language
English
Other organisations
Baylor College of Medicine (BCM)
Duke University Health System
Harbor-UCLA Medical Center
Houston VA Medical Center
Johns Hopkins University
Salem VA Medical Center
Seattle VA Mecial Center
University of Pennsylvania Health System (UPHS) - Penn Medicine
University of Washington (UW)
Doping classes
S1. Anabolic Agents
Substances
Testosterone
Medical terms
Health effects
Legitimate Medical Treatment
Long term effects
Document category
Scientific article
Date generated
14 January 2021
Date of last modification
3 February 2021
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin